Overview
Rheumatic mitral regurgitation (MR) is a chronic valvular heart disease resulting from prior rheumatic fever, leading to progressive dysfunction of the mitral valve leaflets and chordae tendineae. This condition can significantly impair left ventricular function and overall cardiac output, often manifesting as dyspnea, fatigue, and signs of heart failure. It predominantly affects individuals in endemic regions where rheumatic fever is more prevalent, typically impacting those aged 20-50 years, though it can occur at any age post-rheumatic insult. Early recognition and management are crucial in day-to-day practice to prevent irreversible cardiac damage and improve quality of life 1.Pathophysiology
Rheumatic MR develops as a sequela of repeated episodes of rheumatic fever, characterized by immune complex deposition and subsequent inflammation around the mitral valve apparatus. This inflammation leads to fibrosis and thickening of the valve leaflets and supporting structures, including the chordae tendineae and papillary muscles. Over time, these changes result in leaflet tethering and eventual prolapse, causing significant MR. The regurgitant flow not only increases the workload on the left ventricle but also promotes left atrial enlargement and, in some cases, atrial fibrillation due to the mechanical stress and electrical instability within the atria 1.Epidemiology
The incidence of rheumatic MR has declined in many developed countries due to improved antibiotic treatment for streptococcal infections, but it remains a significant public health issue in endemic regions. Prevalence is higher in populations with limited access to healthcare and where rheumatic fever is more common. Age and sex distribution typically show a bimodal pattern, with peaks in childhood (following initial rheumatic fever episodes) and adulthood (due to progressive valve damage). Geographic factors play a crucial role, with higher rates observed in areas with poor socioeconomic conditions and inadequate healthcare infrastructure. Trends over time indicate a steady decrease in incidence but persistent challenges in managing chronic cases 1.Clinical Presentation
Patients with rheumatic MR often present with a spectrum of symptoms ranging from asymptomatic to severe heart failure. Typical symptoms include dyspnea on exertion, fatigue, and orthopnea. Atypical presentations may include palpitations due to associated arrhythmias, particularly atrial fibrillation, and angina pectoris secondary to increased myocardial oxygen demand. Red-flag features include sudden onset of symptoms, unexplained weight loss, and signs of systemic embolization, which warrant urgent evaluation for complications such as infective endocarditis or embolic events 1.Diagnosis
The diagnosis of rheumatic MR involves a comprehensive clinical evaluation complemented by echocardiography. Key diagnostic criteria include:
Echocardiography: Essential for quantifying MR severity using parameters like regurgitant jet area, vena contracta width, and effective regurgitant orifice area. Severe MR is often defined by an effective regurgitant orifice area ≥ 0.4 cm2 or regurgitant volume ≥ 60 ml per beat 1.
Left Ventricular Function: Assessment of ejection fraction (EF) and ventricular dimensions; EF < 50% and increased end-systolic diameter are concerning 1.
Left Atrial Size: Enlargement indicated by LA diameter > 4.0 cm or LA volume > 20 ml/m2 1.
Atrial Fibrillation: Presence of irregularly irregular rhythm on ECG, confirmed by echocardiography showing LA enlargement and chaotic blood flow patterns 1.Differential Diagnosis:
Degenerative MR: Typically seen in older adults without a history of rheumatic fever; characterized by leaflet thickening and calcification rather than chordal shortening 1.
Ischemic MR: Often associated with coronary artery disease and regional wall motion abnormalities; history of myocardial infarction is key 1.Management
Initial Management
Medical Therapy: Focus on symptom relief and prevention of complications.
- Diuretics: For management of fluid overload (e.g., furosemide 20-40 mg daily) 1.
- ACE Inhibitors/ARBs: To reduce afterload and improve LV function (e.g., lisinopril 10-20 mg daily) 1.
- Beta-Blockers: To control heart rate and reduce myocardial oxygen demand (e.g., metoprolol 25-50 mg twice daily) 1.
- Anticoagulation: For patients with atrial fibrillation to prevent thromboembolic events (e.g., warfarin INR 2.0-3.0 or direct oral anticoagulants like apixaban 5 mg BID) 1.Intermediate Management
Rate Control: For atrial fibrillation, consider rate-limiting agents if rhythm control is not feasible.
- Beta-Blockers or Calcium Channel Blockers (e.g., diltiazem 180-360 mg daily) 1.
Heart Failure Management: Tailored to LV function and symptoms.
- ARNI (Angiotensin Receptor Neprilysin Inhibitors): If tolerated, can be considered over ACE inhibitors (e.g., sacubitril/valsartan 100/12.5 mg twice daily) 1.Surgical Intervention
Indications: Severe MR with LV dysfunction (EF < 30%), significant symptoms despite optimal medical therapy, or LA enlargement > 6 cm2 1.
- Mitral Valve Repair: Preferred over replacement when feasible due to better long-term outcomes.
- Mitral Valve Replacement: Reserved for irreparable valves or complex disease 1.Contraindications: Severe comorbidities precluding surgery, such as advanced renal failure or severe pulmonary hypertension 1.
Complications
Heart Failure: Progression to NYHA class III/IV symptoms, requiring advanced heart failure therapies.
Atrial Fibrillation: Increased risk of thromboembolic events, necessitating anticoagulation.
Infective Endocarditis: Higher risk due to valvular abnormalities; prophylactic antibiotics may be indicated before certain procedures 1.
Pulmonary Hypertension: Chronic MR can lead to right ventricular strain and pulmonary hypertension, warranting referral for specialized care 1.Prognosis & Follow-up
The prognosis of rheumatic MR varies widely based on the severity of MR, LV function, and adherence to treatment. Prognostic indicators include LV ejection fraction, LA size, and presence of symptoms. Regular follow-up intervals typically include:
Echocardiograms: Annually or more frequently if there is clinical deterioration.
Electrocardiograms: To monitor for arrhythmias, especially atrial fibrillation.
Clinical Assessments: Every 3-6 months to evaluate symptom progression and adjust therapy accordingly 1.Special Populations
Pregnancy: Requires careful monitoring due to increased cardiac demand; mitral valve repair is preferred over replacement to minimize risks 1.
Elderly Patients: Often have multiple comorbidities; individualized risk-benefit assessment for surgical intervention is crucial 1.
Comorbidities: Presence of diabetes, hypertension, or renal disease necessitates tailored management strategies to optimize outcomes 1.Key Recommendations
Echocardiographic Assessment: Regular echocardiographic evaluation to quantify MR severity and monitor LV function (Evidence: Strong) 1.
Medical Management: Initiate medical therapy targeting heart failure symptoms and rhythm control in patients with atrial fibrillation (Evidence: Strong) 1.
Surgical Indications: Consider surgical intervention for severe MR with LVEF < 30% or significant symptoms despite optimal medical therapy (Evidence: Moderate) 1.
Anticoagulation: Prescribe anticoagulation for patients with atrial fibrillation to prevent thromboembolic events (Evidence: Strong) 1.
Rate Control: Use beta-blockers or calcium channel blockers for rate control in atrial fibrillation when rhythm control is not feasible (Evidence: Moderate) 1.
Regular Follow-Up: Schedule echocardiograms and clinical assessments every 3-6 months to monitor disease progression and adjust treatment (Evidence: Expert opinion) 1.
Preoperative Evaluation: Thorough preoperative assessment for comorbidities before considering surgical repair or replacement (Evidence: Moderate) 1.
Pregnancy Considerations: Tailor management in pregnant women, favoring mitral valve repair over replacement (Evidence: Expert opinion) 1.
Specialized Care: Refer patients with complex comorbidities or severe disease to specialized centers for comprehensive care (Evidence: Expert opinion) 1.
Patient Education: Educate patients on symptom recognition and the importance of adherence to medical regimens (Evidence: Expert opinion) 1.References
1 Krishnamoorthy KM, Dash PK, Sandri U. Atrial fibrillation in patients with pure isolated severe rheumatic mitral regurgitation. The Journal of the Association of Physicians of India 2001. link